argenx develops and commercializes antibody-based therapies targeting severe autoimmune diseases through its proprietary antibody engineering technologies. Its flagship product VYVGART (efgartigimod) is a first-in-class neonatal Fc receptor (FcRn) blocker that reduces circulating pathogenic antibodies and is approved for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The company partners with academic researchers to advance novel immunology treatments.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 948 | — | 245.4 | 873.7% |
| Q3 2025 | 1,127 | — | 344.3 | 349.8% |
| Q4 2025 | 1,287.9 | — | 533 | 1,134.3% |
| Q1 2026 | 1,298 | — | 366 | 162.8% |
| Q2 2026 | 1,515 | 59.8% | 472 | 92.4% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Baker Hughes Company (BKR), Monolithic Power Systems, Inc. (MPWR), NXP Semiconductors N.V. (NXPI), Fastenal Company (FAST), Diamondback Energy, Inc. (FANG), Nebius Group N.V. (NBIS)